Latest Biotech News

Generate Biomedicines priced a landmark IPO, raising roughly $400 million to advance its AI‑designed pipeline and fund pivotal phase 3 trials for its anti‑TSLP antibody GB‑0895 in severe asthma....

Systimmune reported that izalontamab brengitecan (iza‑bren) met both progression‑free survival and overall survival endpoints in a phase III trial in Chinese patients with advanced triple‑negative...

Caris Life Sciences unveiled interim validation results from its Achieve 1 study supporting the planned commercial launch of Caris Detect, a multicancer early detection (MCED) blood assay. In...

Atrium Therapeutics launched as a spinout preserving Avidity Biosciences’ cardiac RNA programs after Novartis closed its $12 billion acquisition of Avidity. Led by former Avidity executives,...

Earendil Labs struck an exclusive deal to access WuXi XDC’s WuXiTecan‑2 payload‑linker technology for next‑generation antibody‑drug conjugates, a transaction valued at up to $885 million in...

Asahi Kasei agreed to acquire German antiviral specialist Aicuris for about $920 million, gaining marketed cytomegalovirus product Prevymis and late‑stage assets including pritelivir for herpes...

UniQure’s market value plunged after FDA Commissioner Marty Makary defended recent rare‑disease therapy rejections on a public broadcast, prompting investor concerns that the agency’s stance could...

The U.S. Food and Drug Administration proposed a draft ‘plausible mechanism’ framework to accelerate development of individualized and ultra‑rare therapies when randomized controlled trials are...

Earendil Labs signed an exclusive pact with WuXi XDC to license the WuXiTecan‑2 payload‑linker platform and tap WuXi XDC’s CRDMO capabilities to advance antibody‑drug conjugates (ADCs). The deal...

Novartis completed its $12 billion acquisition of Avidity Biosciences and simultaneously spun out Atrium Therapeutics to carry forward Avidity’s early cardiac RNA programs. Atrium launched with...

Generate:Biomedicines priced a $400 million Nasdaq IPO, selling 25 million shares at $16 apiece and positioning proceeds to fund two phase 3 asthma trials for its anti‑TSLP antibody GB‑0895 and to...

Caris Life Sciences released interim Achieve‑1 validation data for Caris Detect, its multicancer early detection (MCED) blood test, reporting approximately 95% specificity in 1,505 undiagnosed...

PMV Pharmaceuticals published Phase I results of rezatapopt in the New England Journal of Medicine, reporting objective responses in heavily pretreated patients whose tumors harbored the TP53...

Ginkgo Bioworks agreed to sell its biosecurity business to a consortium of investors in exchange for a minority equity stake in the standalone firm, and reported Q4 2025 revenue of $33.0 million—a...

The U.S. Solicitor General filed a brief urging the Supreme Court to reverse an appeals‑court decision that had revived Amarin’s lawsuit against generic maker Hikma over skinny‑labeling for...

Roche disclosed pricing and performance details for its Axelios 1 sequencing‑by‑expansion system, claiming a $150 list cost to sequence a 30× human genome and positioning the platform for launch...

Columbia University researchers led by Michel Sadelain reported an engineered HLA‑independent T cell (HIT) receptor with ultra‑sensitivity that detects low levels of CD70 and eradicated kidney,...

Natera projected that expanded reimbursement for its minimal residual disease (MRD) assays will drive 2026 growth, confirming submissions to CMS MolDx for Latitude in colorectal cancer and...

PMV Pharmaceuticals reported Phase I data showing the p53 reactivator rezatapopt produced objective responses in heavily pretreated patients whose tumors harbor the TP53 Y220C mutation. The New...

Two separate preclinical advances aim to overcome solid tumor barriers for cellular immunotherapy. Columbia University researchers reported ultra‑sensitive HLA‑independent T (HIT) receptors that...